PglX and its site-specific methyltransferase cousins are being studied as epigenetic editing tools in humans: methylating a specific site in the genome without cutting it is safer than CRISPR for certain applications (no translocations, no double-strand breaks, just a reversible modification). Pre-clinical leads are underway to target latent polyomaviruses (JCV, BKV) that reactivate in immunocompromised patients. BREX is the biological template for this strategy.